Cochrane · systematic review · CD011636
Antithrombin for the prevention of intraventricular hemorrhage in very preterm infants
Bruschettini, M, Romantsik, O, Zappettini, S, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
NeonatalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
3
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 33.3%Low 2 · 66.7%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Antithrombin versus placebo for the prevention of intraventricular hemorrhage in very preterm infants
Population: very preterm infants at risk of intraventricular hemorrhage
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intraventricular hemorrhage (any severity, grade 1 to 4) Antithrombin vs placebo | RR 1.3 [0.87, 1.93] | 2 studies · 175 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Severe Intraventricular hemorrhage (grade 3 to 4) Antithrombin vs placebo | RR 1.04 [0.55, 1.94] | 2 studies · 175 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Neonatal mortality (all‐cause, < 28 days of age) Antithrombin vs placebo | RR 2 [0.62, 6.45] | 2 studies · 182 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |